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Background: Allergen components are very numerous and we need new tools for in-vitro diagnosis of allergy to make Component-Resolved-Diagnosis (CRD). The ImmunoCAP© ISAC (VBC Genomics, Vienna, Austria/Phadia, Uppsala, Sweden) has recently appeared on the market to run CRD. This microarray technique allows the rapid and cost-effective determination of specific IgE antibodies against 103 recombinant or purified allergen components in a single analytical step. The aim of our study was to establish a first validation of the ImmunoCAP© ISAC microarray and to see whether it could be interesting for clinical practice.
Methods: We selected 22 sera of allergic patients on the basis of a clinical anamnesis of Type I allergy and/or on the basis of skin prick testing and/or positive (>0.35 kUA/L) specific IgE tests for recombinant allergens from different kind of allergenic sources. All the samples were screened with the ImmunoCAP© ISAC and then, we compared the 22 results obtained with the sIgE and/or the SPT and/or the anamnesis. Thus, 17 sera had positive (>0.35 kUI/L) specific IgE (sIgE) for different kind of sources (latex, peanut, birch, timothy grass, hazelnut, peach, soja, cat or dog). In all, 136 sIgE for recombinant had been performed. Sixteen patients were selected on the basis of a clinical anamnesis of allergy. Nine patients underwent Skin Prick Tests (SPT) during the medical consultation. We managed a microarray determination on each serum. Then, we compared the results obtained with the sIgE, the SPT or the anamnesis.
Results: Most of the allergens tested had the same results with ISAC© and with SPT (regarding positive and negative tests). Amongst the 136 positive sIgE against recombinant allergens tested, the ImmunoCAP© ISAC found 132 times concordant results. The ImmunoCAP© ISAC provided results in agreement with the anamnesis in every cases. It permitted also to find out an allergy to a major allergen of peanut and of hazelnut.
Conclusions: The ImmunoCAP© ISAC showed performance characteristics comparable to the current diagnostic tests (sIgE determination, SPT). It reflected correctly the clinical anamnesis. This technique allowed us to see, in a single analytical step, the allergen sensitization profile of a patient. Most importantly, it permitted to avoid a hazardous oral provocation test in an allergic patient. In the future, this technique could be very useful in monitoring polysensitized patients and atopic patients.


